Publicaciones Científicas
Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia
Megias-Vericat, JE; Martinez-Cuadron, D; Herrero, MJ; Rodriguez-Veiga, R; Solana-Altabella, A; Boluda, B; Ballesta-Lopez, O; Cano, I; Acuna-Cruz, E; Cervera, J; Poveda, JL; Sanz, MA; Alino, SF;…
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group
Palanques-Pastor, T; Megias-Vericat, JE; Martinez, P; Lorenzo, JLL; Navascues, JC; Macias, GR; Cano, I; Sangerman, MA; Vicente, MBV; Algarra, JLA; Foncillas, MA; Herrera, P; Prieto, CB; Vives, S;…
Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia
Fabiani, E; Cicconi, L; Nardozza, AM; Cristiano, A; Rossi, M; Ottone, T; Falconi, G; Divona, M; Testi, AM; Annibali, O; Castelli, R; Lazarevic, V; Rego, E; Montesinos, P; Esteve, J; Venditti, A;…
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial
Ayala, R; Rapado, I; Onecha, E; Martinez-Cuadron, D; Carreno-Tarragona, G; Bergua, JM; Vives, S; Algarra, JL; Tormo, M; Martinez, P; Serrano, J; Herrera, P; Ramos, F; Salamero, O; Lavilla, E; Gil, C;…
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients
Sanchez, MPM; Megias-Vericat, JE; Rodriguez-Veiga, R; Vives, S; Bergua, JM; Torrent, A; Suarez-Varela, S; Boluda, B; Martinez-Lopez, J; Cano-Ferri, I; Acuna-Cruz, E; Torres-Minana, L; Martin-Herreros…
Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study
Rodriguez-Arboli, E; Martinez-Cuadron, D; Rodriguez-Veiga, R; Carrillo-Cruz, E; Gil-Cortes, C; Serrano-Lopez, J; del Castillo, TB; Martinez-Sanchez, MD; Rodriguez-Medina, C; Vidriales, B; Bergua, JM;…
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia
Vives, S; Martinez-Cuadron, D; Burgues, JB; Algarra, L; Tormo, M; Martinez-Sanchez, MP; Serrano, J; Herrera, P; Ramos, F; Salamero, O; Lavilla, E; Lopez-Lorenzo, JL; Gil, C; Vidriales, B; Falantes,…
Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial
Simoes, C; Paiva, B; Martinez-Cuadron, D; Bergua, JM; Vives, S; Algarra, L; Tormo, M; Martinez, P; Serrano, J; Herrera, P; Ramos, F; Salamero, O; Lavilla, E; Gil, C; Lopez, JL; Vidriales, MB;…
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia
Paiva, B; Vidriales, MB; Sempere, A; Tarin, F; Colado, E; Benavente, C; Cedena, MT; Sanchez, J; Caballero-Velazquez, T; Cordon, L; Garces, JJ; Simoes, C; Martinez-Cuadron, D; Bernal, T; Botella, C;…
Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features
Calvo, X; Garcia-Gisbert, N; Parraga, I; Gibert, J; Florensa, L; Andrade-Campos, M; Merchan, B; Garcia-Avila, S; Montesdeoca, S; Fernandez-Rodriguez, C; Salido, M; Puiggros, A; Espinet, B; Colomo, L;…